<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01756170</url>
  </required_header>
  <id_info>
    <org_study_id>WZMC-11352</org_study_id>
    <nct_id>NCT01756170</nct_id>
  </id_info>
  <brief_title>Postoperative Chemoradiation v.s Radiotherapy for Lymph Node Negative Cervical Cancer Patients</brief_title>
  <official_title>Phase III Randomized Trial of Comparing Chemoradiotherapy vs. Radiotherapy Alone in Lymph Node Negative Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>xie congying</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wenzhou Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III study is designed to examine if low-risk (lymph node negative), stage I a2-II
      b cervical cancer patients treated by paclitaxel/cisplatin chemoradiation have greater
      toxicities but similar survival rate as those treated by radiotherapy alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cervical carcinoma is one of the most common gynecologic cancers worldwide. Concurrent
      radiotherapy with cisplatin-based chemotherapy has become the standard treatment for patients
      with high risk factors cervical cancer. However, the treatment modality in patients with
      low-risk (lymph node negative) is still disputable. It is not yet known whether
      cisplatin-based chemoradiotherapy are more effective than radiotherapy alone in treating
      these patients.

      Therefore, the investigators are going to perform the efficacy and safety study of
      postoperative concurrent paclitaxel/cisplatin chemoradiotherapy vs. radiotherapy alone in
      lymph node negative patients with early-stage cervical cancer following radical hysterectomy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>1 year</time_frame>
    <description>assessed by NCI Common Terminology Criteria v3.0</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive radiotherapy alone as in arm 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will postoperatively receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3 intravenously every 4 weeks with radiation. Radiotherapy consisted of 46-50 gray (5 x 2.0 gray/week) on pelvic area.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undertaken radical hysterectomy with diagnosis of invasive cervical cancer (non-small
             cell type)

          -  Negative lymph node

          -  At least two risk factors (interstitial infiltration of greater than 1/3, vascular or
             lymphatic involvement, cervix neoplasms larger than 4 cm, nerve involvement)

          -  Eastern Cooperative Oncology Group 0-2

          -  Expected life span over 6 months.

          -  No distant metastasis

          -  Adequate bone marrow functions (absolute neutrophil count≥ 1,500/ul, blood platelet≥
             100,000/ul, haemoglobin≥ 10g/dl)

          -  Adequate renal functions(serum creatinine ≤ 1.5mg/dl)

          -  Adequate liver functions (serum bilirubin ≤ 1.5mg/dl, aspartate
             aminotransferase/alanine aminotransferase ≤ 3 times(normal value)

          -  Written informed consent

        Exclusion Criteria:

          -  Previous history of chemotherapy or radiation

          -  Hypersensitive reaction to platinum/paclitaxel agent

          -  History of other cancer

          -  Concurrent systemic illness not appropriate for chemotherapy

          -  Active infection requiring antibiotics

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Congying Xie, MD</last_name>
    <role>Study Director</role>
    <affiliation>the 1st Affiliated Hospital of Wenzhou Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>congying xie, MD</last_name>
    <phone>+86-577-88069316</phone>
    <email>wzxiecongying@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical College</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>congying xie, MD</last_name>
      <phone>+86-577-88069316</phone>
      <email>wzxiecongying@163.com</email>
    </contact>
    <investigator>
      <last_name>congying xie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2012</study_first_submitted>
  <study_first_submitted_qc>December 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2012</study_first_posted>
  <last_update_submitted>April 27, 2016</last_update_submitted>
  <last_update_submitted_qc>April 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wenzhou Medical University</investigator_affiliation>
    <investigator_full_name>xie congying</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>postoperative therapy</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

